



IBT BIOSERVICES

4 Research Court, Suite 300
 Rockville, MD 20850
 877-411-2041
 Services@ibtbioservices.com

Mouse anti-SUDV GP mAb (16F6)

Catalog #: 0280-001

Lot #: 2003004

Description: Purified mouse monoclonal antibody 16F6 that binds to a conformation epitope on Sudan virus (SUDV) glycoprotein (GP). This antibody demonstrates protection against SUDV both *in vitro* and *in vivo* (Dias et al., 2011 Nov 20, *Nat Struct Mol Biol.* 18 (12): 1424-1427).

Immunogen: Venezuelan equine encephalitis virus replicons encoding SUDV GP and gamma-radiation-inactivated SUDV-Boniface were used to generate the original mouse monoclonal antibody.

Supplied: 100 µg is supplied in phosphate buffered saline at a concentration of 1.315 mg/mL. No preservative is added.

Clonality: Monoclonal of the IgG₁ isotype

Relevance: The antibody can be used as a positive control for plaque reduction neutralization test (PRNT) and neutralization assay using SUDV-GP pseudotyped VSV.

Recommended Dilutions:

ELISA: Assay-dependent dilution.

WB: Not recommended because 16F6 recognizes conformational epitope.

Storage: 2-3 weeks +4°C, -20°C long term


Cross Reactivity:

In ELISA: No cross-reactivity was observed to Ebola virus (EBOV) or Marburg virus (MARV) virus-like particles (VLP).

Related Products:

IBT provides a wide array of anti-filovirus specific antibodies, recombinant proteins and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Neutralization Data:



Anti-SUDV mouse mAb 16F6, starting at 50 µg/mL followed by serial dilutions, was incubated with the VSV pseudotyped with SUDV GP (SUDV-VSV) containing luciferase gene for one hour prior to adding to Vero cells. Infectivity was determined the next day by assessing luciferase activity. We found that 22 ng/mL of 16F6 lot 1709002 reduced infectivity of SUDV-VSV by 50% and 1 µg/mL of 16F6 neutralized 100%.

ELISA Data:

16F6 conc. (µg/mL)	Coating Antigen: 10 µg VLP/mL or 1 µg VLP/well			Coating Antigen: 1 µg rGPΔTM/mL or 100 ng rGPΔTM/well		
	SUDV	EBOV	MARV	SUDV	EBOV	MARV
10.0000	1.800	0.108	0.065	3.447	0.353	0.360
3.1623	1.794	0.150	0.066	3.405	0.292	0.170
1.0000	1.753	0.079	0.075	3.383	0.074	0.098
0.3162	1.723	0.357	0.072	3.368	0.062	0.074
0.1000	1.385	0.058	0.087	3.004	0.054	0.065
0.0316	1.006	0.054	0.107	2.231	0.053	0.077
0.0100	0.469	0.075	0.061	1.243	0.050	0.135
0.0032	0.225	0.066	0.070	0.578	0.058	0.131
0.0010	0.128	0.086	0.085	0.237	0.053	0.057
0.0003	0.120	0.092	0.078	0.118	0.058	0.056
0.0001	0.076	0.101	0.063	0.094	0.063	0.065
0.0000	0.065	0.074	0.074	0.083	0.080	0.061

VLP's were diluted to 10 µg/mL in PBS and coated on MaxiSorp™ plates. Recombinant glycoproteins (rGPΔTM) with His-tag were diluted to 1 µg/mL in PBS and coated on Ni-NTA HisSorb™ plates. Anti-SUDV GP mouse mAb 16F6 was serially diluted semi-log from 10 µg/mL and incubated on the coated plates. Washed plates were detected with anti-mouse IgG-HRP conjugate and TMB substrate. OD₆₅₀ is reported above.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2020. Integrated BioTherapeutics, Inc. All rights reserved.